Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing Rivaroxaban and Asprin (RA) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 24/October/2017, 11.24 pm

Natural product-based therapy for Cardiomyopathy: Aspalathin, found abundantly in Rooibos/Aspalathus linearis, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 24/October/2017,  10.42 pm
October 24, 2017
Molecular therapy for body weight control, energy homeostasis and TIIDM:  Chenodeoxycholic acid (CDCA) [Trade name: Ursodiol] decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 25/October/2017, 12.01 am
October 24, 2017
Show all

Introduction: What they say

A study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761)by Prof Tzahor E, D’Uva E, and others.

A recent study from the Population Health Research Institute, McMaster University and Hamilton Health Sciences, David Braley Research Bldg., Hamilton General Hospital, 237 Barton St. E., Hamilton, ON L8L 2X2, Canada shows that “Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.” This study was published, in the 27 August  2017 issue of the journal “N Engl J Med.” (the number 1 journal in “Clinical medicine” with an impact factor of 72.406), by Dr. Eikelboom, Stuart J. Connolly and others.


What we say: 

On the foundation of these interesting findings, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing Rivaroxaban and Asprin (RA) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene  [easy_payment currency=”USD”]


From significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) out of 55 million deaths that occur every year nearly 18.33 millions deaths are due to cardiovascular causes; (3) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (4) 85% of people over 80 years are susceptible to cardiovascular diseases;(5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year from 2030 onwards, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to Therapeutic opportunity: 

Although Dr. Eikelboom’s research team has shown recently that treating patients  with a combination of Rivaroxaban (2.5 mg twice daily) and Asprin (100 mg/day) ameliorates outcome of stable cardiovascular disease than treating them with either drug alone, its mechanism of action is not known.

Figure1. Mechanistic insights into how a pharmaceutical mixture encompassing Rivaroxaban and Asprin (RA) may promote cardiac dedifferentiation and regeneration. RA, by increasing the expression of its target gene, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

This study provides, for the first time, mechanistic insights into how  a combination of Rivaroxaban and Asprin may improve stable cardiovascular disease. A pharmaceutical mixture encompassing  Rivaroxaban and Asprin (RA), by increasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; (3) cardiomyocyte (CM) redifferentiation and regeneration; (4) improve insulin sensitivity; (5) decrease cardiac ageing; and (6) promote longevity (Figure 1).  

Thus, pharmacological formulations encompassing ” Rivaroxaban and Asprin or their analogues, either alone in combination other drugs or compounds may promote cardiac regeneration” may be used to promote cardiomyocyte regeneration following myocardial infarction

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed mechanistic information: How  a pharmaceutical mixture encompassing Rivaroxaban and Asprin  increases the expression of  ERBB2/Her2

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing Rivaroxaban and Asprin (RA) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 24/October/2017, 11.24 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.